Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Apatinib Combined With Oxaliplatin and Gimeracil and Oteracil Porassium Capsules Neoadjuvant Therapy for Locally Advanced Gastric Cance: A Multicentre, One-armed, Clinical Pilot Trial

Next Previous
X
Search
Trial Profile

Apatinib Combined With Oxaliplatin and Gimeracil and Oteracil Porassium Capsules Neoadjuvant Therapy for Locally Advanced Gastric Cance: A Multicentre, One-armed, Clinical Pilot Trial

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 06 Feb 2020

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Gimeracil (Primary) ; Oteracil (Primary) ; Oxaliplatin (Primary) ; Rivoceranib (Primary)
  • Indications Adenocarcinoma; Gastric cancer
  • Focus Therapeutic Use

    • Most Recent Events

    • 04 Feb 2020 Planned End Date changed from 30 Jun 2024 to 11 Dec 2024.
    • 04 Feb 2020 Status changed from recruiting to active, no longer recruiting.
    • 25 Jan 2020 Results of apatinib combined with SOX neoadjuvant therapy for locally advanced gastric cancer has been presented at the 2020 Gastrointestinal Cancers Symposium

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top